Postoperative follow-up of gastric adenocarcinoma with neoplastic markers and 18-FDG-PET/TC

Annali Italiani di Chirurgia

Volumn 78, Issue 6, 2007, Pages 481-485

  Patriti, Alberto ^a   Graziosi, Luigina ^a   Baffa, Nicodemo ^b   Pacifico, Eugenio ^b   Lamprini, Papaefthimiou ^a   Valiani, Saverio ^a   Gullà, Nino ^a   Donini, Annibale ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

CA72.4; Carcinosis CA19.9; CEA; FDG PET TC; Gastrectomy; Gastric cancer; Liver metastasis; Neoplastic markers; Recurrence

Indexed keywords

CA 19-9 ANTIGEN; CA 72 4 ANTIGEN; CA-72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; TUMOR ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STOMACH TUMOR; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 47249084242     PISSN: 0003469X     EISSN: 2239253X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Whiting J, Sano T, Saka M., Fukagawa T, Katai H, Sasako M: Follow-up of gastric cancer: a review. Gastric Cancer, 2006; 9:74-8.
2. Kodera Y, Ito S, Yamamura Y., Mochizuki Y, Fujiwara M, Hibi K., Ito K, Akiyama S, Nakao A: Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol, 2003; 10:898-902.
3. Yoo CH, Noh SH, Shin D.W., Choi SH, Min JS: Recurrence following curative resection for gastric carcinoma. Br J Surg, 2000; 87:236-42.
4. Kobayashi M, Tsuburaya A, Nagata N., Miyashita Y, Oba K, Sakamoto J: A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer. Gastric Cancer, 2006; 9:114-19.
5. Sakamoto Y, Ohyama S, Yamamoto J., Yamada K, Seki M, Ohta K., Kokudo N, Yamaguchi T, Muto T., Makuuchi M: Surgical resection of liver metastases of gastric cancer: An analysis of a 17-year experience with 22 patients. Surgery 2003; 133:507-11.
6. Sastre J, Garcia-Saenz JA, Diaz-Rubio E: Chemotherapy for gastric cancer. World J Gastroenterol, 2006; 12:204-13.
7. Yamakado K, Nakatsuka A, Takaki H., Mori Y, Tonouchi H, Kusunoki M., Kida H, Takeda K: Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer. J Vasc Interv Radiol, 2005; 16:1747-751.
8. Shin SJ, Chun SH, Kim K.O., Kim MK, Lee KH, Hyun MS, Bae S.H., Ryoo HM, Do YR, Kwon KY, Song HS: The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: A rnulticenter phase II study. Korean J Intern Med, 2005; 20:135-40.
9. Ashley T: Using predictive value, sensitivity and specificity to interpret laboratory tests: PSA for the diagnosis of prostate cancer. J Insur Med, 2005; 37:261-63.
10. Ott K, Fink U, Becker K., Stahl A, Dittler HJ, Busch R, Stein H., Lordick F, Link T, Schwaiger M., Siewert JR, Weber WA: Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial J Clin Oncol, 2003; 21:4604-610.
11. Ott K, Weber WA, Fink U, Helmberger H., Becker K, Stein HJ, Muller J, Schwaiger M., Siewert JR: Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J Surg, 2003; 27:1035-1039.
12. Stahl A, Ott K, Weber W.A., Becker K., Link T, Siewert JR, Schwaiger M, Fink U: FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging, 2003; 30:288-95.
13. Cancer JRSfG: Japanese classification of gastric carcinoma. Tokyo: Kanehara, 1995.
14. Siewert JR, Feith M, Stein HJ: Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: Relevance of a topographic-anatomic subclassification. J Surg Oncol, 2005; 90:139-46; discussion 146.
15. Minghini A, Weireter LJ, Jr., Perry RR: Specificity of elevated CA 19-9 levels in chronic pancreatitis. Surgery, 1998; 124:103-5.
16. Yoshida EM, Scudamore CH, Erb S.R., Owen DA, Silver HK: Markedly elevated serum CA 19-9 levels in a case of chronic pancreatitis. Can J Surg, 1995; 38:83-86.
17. Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L., Roviello F: Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg, 2001; 181:16-19.
18. Roviello F, Garosi L, Marrelli D., De Srefano A, Udhris C, Messano A., Pinto E: Preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Minerva Chir, 1996; 51:133-39.
19. Takahashi Y, Takeuchi T, Sakamoto J., Touge T, Mai M, Ohkura H., Kodaira S, Okajima K, Nakazato H: The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer, 2003; 6:142-45.
20. Wu CH, Lin SR, Hsieh J.S., Chen FM, Lu CY, Yu FJ, Cheng T.L., Huang TJ, Huang SY, Wang JY: Molecular detection of disseminated tumor cells in the peripheral blood of patients with gastric cancer: evaluation of their prognostic significance. Dis Markers, 2006; 22:103-9.
21. Victorzon M, Haglund C, Lundin J., Roberts PJ: A prognostic value of CA 19-9 but not of CEA in patients with gastric cancer. Eur J Surg Oncol, 1995; 21:379-84.
22. Li YM, Zhan WH, Han F.H., He YL, Peng JS, Cai SR, Ma J.P., Zhao G: Clinicopathological analysis of synchronous liver metastasis in gastric cancer and evaluation of surgical outcomes. Zhonghua Wei Chang Wai Ke Za Zhi, 2006; 9:127-30.
23. Noda K, Umekita N, Shiba Y., Ookubo T, Inoue S, Kitamura M: Indication and meaning of hepatic resection for metastatic liver tumors from gastric cancer. Gan To Kagaku Ryoho, 2005; 32:1688-690.
24. Carditello A, Scisca C, Stilo F., Parisi A, Basile M: The possible role of radiofrequency as complementary treatment of locally advanced gastric cancer. Ann Ital Chir, 2005; 76:39-41.
25. Roh HR, Suh KS, Lee H.J., Yang HK, Choe KJ, Lee KU: Outcome of hepatic resection for metastatic gastric cancer. Am Surg, 2005; 71:95-99.